A Randomized Phase II Translational Research Study in Patients with Advanced Head and Neck Cancer to Investigate the Effects of Standard Chemoradiation and Add-on Concurrent Epidermal Growth Factor Receptor (EGFR) Inhibitor +/- Consolidation EGFR Inhibitor

Riesterer O.; Pruschy M.; Bender S.; Sharma A.; Bogowicz M.; Tanadini-Lang S.; Stieb S.; Bertogg K.; Ikenberg K.; Huber G.; Bredell M.; Schmid S.; Veit-Haibach P.; Rordorf T.; Held U.; Glanzmann C.; Studer G.

首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >A Randomized Phase II Translational Research Study in Patients with Advanced Head and Neck Cancer to Investigate the Effects of Standard Chemoradiation and Add-on Concurrent Epidermal Growth Factor Receptor (EGFR) Inhibitor +/- Consolidation EGFR Inhibitor

【24h】

A Randomized Phase II Translational Research Study in Patients with Advanced Head and Neck Cancer to Investigate the Effects of Standard Chemoradiation and Add-on Concurrent Epidermal Growth Factor Receptor (EGFR) Inhibitor +/- Consolidation EGFR Inhibitor

机译：高级头部和颈部癌症患者的随机期II转化研究研究，探讨标准化学校长和附加型同时表皮生长因子受体（EGFR）抑制剂+/-固结EGFR抑制剂的影响

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《International Journal of Radiation Oncology, Biology, Physics》 |2019年第1suppla期|共3页
作者
Riesterer O.; Pruschy M.; Bender S.; Sharma A.; Bogowicz M.; Tanadini-Lang S.; Stieb S.; Bertogg K.; Ikenberg K.; Huber G.; Bredell M.; Schmid S.; Veit-Haibach P.; Rordorf T.; Held U.; Glanzmann C.; Studer G.;
展开▼
作者单位

Univ Zurich Univ Zurich Hosp Dept Radiat Oncol Zurich Switzerland;

Univ Zurich Lab Mol Radiobiol Zurich Switzerland;

Univ Zurich Lab Mol Radiobiol Zurich Switzerland;

Univ Zurich Lab Mol Radiobiol Zurich Switzerland;

Univ Zurich Univ Zurich Hosp Dept Radiat Oncol Zurich Switzerland;

Univ Zurich Univ Zurich Hosp Dept Radiat Oncol Zurich Switzerland;

Univ Zurich Univ Zurich Hosp Dept Radiat Oncol Zurich Switzerland;

Univ Zurich Univ Zurich Hosp Clin Trials Ctr Zurich Switzerland;

Univ Zurich Univ Zurich Hosp Dept Pathol Zurich Switzerland;

Univ Zurich Univ Zurich Hosp Dept Otorhinolaryngol Zurich Switzerland;

Univ Zurich Univ Zurich Hosp Clin Oral &

Maxillofacial Surg Zurich Switzerland;

Otorhinolaryngol Clin Bethanien Zurich Switzerland;

Univ Zurich Univ Zurich Hosp Dept Nucl Med Zurich Switzerland;

Univ Zurich Univ Zurich Hosp Dept Med Oncol Zurich Switzerland;

Univ Zurich Epidemiol Biostat &

Prevent Inst Dept Biostat Zurich Switzerland;

Univ Zurich Univ Zurich Hosp Dept Radiat Oncol Zurich Switzerland;

Univ Zurich Univ Zurich Hosp Dept Radiat Oncol Zurich Switzerland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词

相似文献

外文文献
中文文献
专利

1. 第一代酪氨酸激酶抑制剂治疗中发生进展的非小细胞肺癌血浆表皮生长因子受体(EGFR) T790M突变提示了失败部位并预测了临床预后:一项前瞻性观察研究 [J] . Shirong Zhang, Lucheng Zhu, Bing Xia, 癌症（英文版） . 2018,第009期
2. A Randomized Phase II Translational Research Study in Patients with Advanced Head and Neck Cancer to Investigate the Effects of Standard Chemoradiation and Add-on Concurrent Epidermal Growth Factor Receptor (EGFR) Inhibitor +/- Consolidation EGFR Inhibitor [J] . Riesterer O., Pruschy M., Bender S., International Journal of Radiation Oncology, Biology, Physics . 2019,第1Suppla期

机译：高级头部和颈部癌症患者的随机期II转化研究研究，探讨标准化学校长和附加型同时表皮生长因子受体（EGFR）抑制剂+/-固结EGFR抑制剂的影响
3. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [J] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Frontiers in Oncology . 2019,第4期

机译：卡巴替尼+厄洛替尼在晚期表皮生长因子受体（ EGFR ）-突变型非小细胞肺癌中进展性疾病的表皮生长因子受体酪氨酸激酶抑制剂治疗的II期临床试验：加利福尼亚癌症协会II期试验（NCI 9303）
4. Phase IB/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer (vol 36, pg 3101, 2018) [J] . Wu Y-L, Zhang L., Kim D-W Journal of Clinical Oncology . 2019,第3期

机译：Capmatinib（INC280）的IB / II研究加上表皮生长因子受体（EGFR）抑制剂治疗患者患有EGFR突变的患者的抑制剂治疗后的吉非替尼研究，符合因子诱惑的非小细胞肺癌（Vol 36，PG 3101,2018 ）
5. QSAR Study of Quinazoline Derivatives as Inhibitor of Epidermal Growth Factor Receptor-Tyrosine Kinase (EGFR-TK) [C] . La Ode Aman, Widisusanti Abdulkadir, Julitha Geybie Rembet, International Conference on Computation for Science and Technology . 2015

机译：喹唑啉衍生物作为表皮生长因子受体 - 酪氨酸激酶（EGFR-TK）抑制剂的QSAR研究
6. The role of MyD88-dependent receptors in the anti-tumor efficacy of the EGFR inhibitor erlotinib in head and neck cancer. [D] . Koch, Adam Taylor. 2014

机译：MyD88依赖性受体在EGFR抑制剂埃洛替尼在头颈癌的抗肿瘤功效中的作用。
7. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [O] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, 2007

机译：卡博替尼+厄洛替尼在晚期表皮生长因子受体（EGFR）-突变型非小细胞肺癌进展性疾病中进行表皮生长因子受体酪氨酸激酶抑制剂治疗的II期试验：加利福尼亚癌症协会II期试验（NCI 9303）
8. A Randomized Phase II Translational Research Study in Patients with Advanced Head and Neck Cancer to Investigate the Effects of Standard Chemoradiation and Add-on Concurrent Epidermal Growth Factor Receptor (EGFR) Inhibitor ± Consolidation EGFR Inhibitor [O] . O. Riesterer, M. Pruschy, S. Bender, 2019

机译：高级头部和颈部癌患者的随机期II转化研究研究，探讨标准化学校长和加载同时表皮生长因子受体（EGFR）抑制剂±固结EGFR抑制剂的影响

A Randomized Phase II Translational Research Study in Patients with Advanced Head and Neck Cancer to Investigate the Effects of Standard Chemoradiation and Add-on Concurrent Epidermal Growth Factor Receptor (EGFR) Inhibitor +/- Consolidation EGFR Inhibitor

著录项

相似文献

相关主题

期刊订阅